">
GC Biopharma will acquire ABO Holdings for $96 million to enhance its immunoglobulin medication Alyglo's supply chain.
The company's plant in Ochang, North Chungcheong is buzzing with the production of the blood product, the first by a Korean pharmaceutical to secure FDA approval.
Korea JoongAng Daily Sitemap